Glycolipids Substitute PEG lipids in Lipid Nanoparticles for mRNA Delivery

Area of Science:

• Biotechnology
• Drug Delivery
• Immunology

Background:

• Lipid nanoparticles (LNPs) are key for mRNA delivery.
• Poly(ethylene glycol) (PEG) lipids in LNPs can cause immunogenicity, limiting repeated use.
• Developing PEG-free LNP formulations is crucial for improved therapeutic strategies.

Purpose of the Study:

• To create a novel, PEG-free LNP formulation using glycolipids as alternatives to PEG lipids.
• To investigate the physicochemical properties and self-assembly of these new glycolipid-based LNPs.
• To evaluate the in vivo immunogenicity, biodistribution, and therapeutic efficacy of the developed LNPs.

Main Methods:

• Synthesized novel glycolipids by conjugating maltoheptaose (G7) to alkyl diamines using one-pot Borch reductive amination.
• Formulated stable LNPs using optimized G7-based glycolipids with C14 tails (G7B2).
• Assessed LNP physicochemical properties, in vivo splenic accumulation, anti-PEG antibody response, repeated administration efficacy, and antitumor activity using a B16F10-OVA melanoma model with G7B2-OVA mRNA.

Main Results:

• G7B2 glycolipids self-assembled into stable LNPs with favorable physicochemical properties.
• G7B2 LNPs demonstrated enhanced splenic accumulation and minimized anti-PEG antibody production in vivo.
• Repeated administration of G7B2 LNPs maintained consistent mRNA delivery efficiency, unlike conventional PEGylated LNPs.
• G7B2-OVA mRNA achieved significant antitumor efficacy in a preclinical melanoma model.

Conclusions:

• Chemically designed glycolipids serve as effective, immunogenically inert replacements for PEG lipids in LNP formulations.
• G7B2 LNPs offer a promising platform for next-generation mRNA therapeutics, overcoming limitations of PEGylated systems.
• This strategy enables tunable and stable LNP development for enhanced drug delivery and reduced immunogenicity.